1-6 of 6
Christopher D Fletcher
Close
Sort by
Journal Articles

Minimal Residual Disease (MRD) Testing By Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study

Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre, Christopher D Fletcher, Saurabh A Rajguru, Priyanka A Pophali, Mariah Endres, Mitch Howard, Tim Wassenaar, Ruth Callaway Warren, Ryan J Mattison, Kari B Wisinski, Julie E Chang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4407.
https://doi.org/10.1182/blood-2023-173871
Published: 2023
Journal Articles

Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404

Jonathon B. Cohen, Opeyemi Jegede, Craig A. Portell, Mehdi Hamadani, Catherine S. Diefenbach, Kevin A. David, Christopher D. Fletcher, Daniel J. Landsburg, Suparna Mantha, Brad S. Kahl
Journal: Blood
Blood (2022) 140 (Supplement 1): 6487–6488.
https://doi.org/10.1182/blood-2022-164710
Published: 2022
Journal Articles

Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403)

Craig A. Portell, Opeyemi Jegede, Nina D. Wagner-Johnston, Grzegorz S. Nowakowski, Christopher D. Fletcher, Jonathon B. Cohen, Kevin A. David, Nadia Khan, Lori J Rosenstein, Brad S. Kahl
Journal: Blood
Blood (2021) 138 (Supplement 1): 814.
https://doi.org/10.1182/blood-2021-145217
Published: 2021
Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Gabriel K. Griffin, Jason L. Weirather, Margaretha G. M. Roemer, Mikel Lipschitz, Alyssa Kelley, Pei-Hsuan Chen, Daniel Gusenleitner, Erin Jeter, Christine Pak, Evisa Gjini, Bjoern Chapuy, Michael H. Rosenthal, Jie Xu, Benjamin J. Chen, Aliyah R. Sohani, Scott B. Lovitch, Jeremy S. Abramson, Jeffrey J. Ishizuka, Austin I. Kim, Caron A. Jacobson, Ann S. LaCasce, Christopher D. Fletcher, Donna Neuberg, Gordon J. Freeman, F. Stephen Hodi, Kyle Wright, Azra H. Ligon, Eric D. Jacobsen, Philippe Armand, Margaret A. Shipp, Scott J. Rodig
Journal: Blood
Blood (2021) 137 (10): 1353–1364.
https://doi.org/10.1182/blood.2020006464
Published: 2021
Includes: Supplemental data
Journal Articles

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Julie E Chang, MD, Vaishalee P. Kenkre, MD, Christopher D. Fletcher, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Kyungmann Kim, PhD, Grace Yi Chen, Kaitlin Chambers
Journal: Blood
Blood (2019) 134 (Supplement_1): 5470.
https://doi.org/10.1182/blood-2019-124489
Published: 2019
Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1541.
https://doi.org/10.1182/blood-2019-127494
Published: 2019